COVID-19
Conditions
Interventions
Patients will be randomized to the following 3 groups.
1) Group with 150mg/day
In addition to ordinary therapyies for COVID-19, the study drug 150 mg/day will be administered to patients for 14 days.
Sponsors
Iwahori Kota
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who are positive for SARS-CoV-2 by PCR or antigen test 2) Patients who do not need continuous (24h) oxygen inhalation 3) Patients who can eat and drink 4) Patients older or equal to 20 years old and younger than 75 years old 5) Patients who can sign the informed consent form by themselves
Exclusion criteria
Exclusion criteria: 1) Patients with hypersensitivity for tetracycline compound 2) Patients showing SpO2 = the standard value) 5) Patients with kidney failure (eGFR < 30 ml/min/1.73m2) 6) Patients who had a COVID-19 vaccination 7) Patients who are considered unsuitable for the study by the PI or sub investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change rate of CD8+ T cells between before and 7 days after the administration of the study drug | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Duration between the start day of study drug administration and the time when patients need continuous (24h) oxygen therapy 2) The change and change rate of SpO2 3) The change of CD8+ T cells between before and 7 days after the administration of the study drug 4) Negative conversion rate of COVID-19 5) The change rate of COVID-19 viral quantity measured by quantitative PCR 6) The change rate of IL-6, IFN-gamma, TNF-alpha 7) The change rate of CD4, CD19 8) The improvement rate of NEWS score 9) The change of clinical status measured by 7 degrees of ordinal scale score 10) The change of clinical symptoms (e.g. cough, dyspnea) self-reported by patients | — |
Contacts
Public ContactYukio Tanaka
Department of Medical Innovation, Osaka University Hospital
Outcome results
None listed